Pfizer Inc. (NYSE: PFE) said it agreed to sell its Capsugel business, a maker of hard capsules, to private equity firm Kohlberg Kravis Robert & Co. for $2.375 billion in cash.
Pfizer Inc. (NYSE: PFE) said on Monday it has received a Refusal-to-File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company’s oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).
Regulatory pressure prompted Sanofi-Aventis and Merck & Co to abandon plans for a joint animal health powerhouse with $5 billion in sales.
Drugmaker Eli Lilly , which faces plunging sales due to competition and lapsing patents, will not merge with another peer to ride out any rough times ahead, chief executive John Lechleitr said on Saturday.
Microsoft and federal agents took down Rustock, a botnet responsible at its peak for nearly half of the world's spam.
The companies whose shares are moving in pre-market trade on Monday are: Family Dollar Stores, Lorillard, Frontier Communications, Ameren, PNC Financial Services, MetLife, Novellus Systems, Novellus Systems, Marshall & Ilsley and Pfizer.
Health regulators want more data on Protalix Biotherapeutics Inc and Pfizer Inc's experimental drug for Gaucher disease before deciding whether to approve the therapy for patients with the rare genetic disorder.
Biogen Idec stock price can appreciate to the mid $70s based on five areas of potential upside, according to RBC Capital Markets. The brokerage upgraded its rating on shares of the biotechnology company to outperform from sector perform and increased its price target to $75 from $60.
Pfizer Inc said it has settled all outstanding lawsuits involving accusations that it tested the experimental antibiotic Trovan on children in Nigeria during a 1996 meningitis outbreak without receiving adequate prior consent.
Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday.
A new virtual entrepreneurship hub from the New York University will now enable technology innovation and startup formation within the campus community by providing a growing array of entrepreneurial resources, programs, and activities online.
The top pre-market NASDAQ stock market gainers are: Glu Mobile, Orexigen Therapeutics, Veeco Instruments, Progenics Pharmaceuticals, and InterDigital. The top pre-market NASDAQ stock market losers are: Questcor Pharmaceuticals, Yongye International, Kandi Technologies, China Agritech, and Cognizant Technology Solutions.
World stocks punched fresh 29-month highs on Wednesday, lifted by strong data pointing to sustained global economic recovery, continuing positive corporate earnings and easing concerns about Egypt.
Swiss drugmaker Roche struck a cautious note on 2011, as the sector grapples with U.S. healthcare reforms and a push in Europe for lower drug prices, after growth of its top-seller Avastin slowed sharply in 2010.
Pfizer Inc Chief Executive Ian Read is slashing the massive research budget at the world's largest drugmaker to deliver on a 2012 profit forecast and allay Wall Street concerns the company has become too large.
The Dow Jones Industrial Average and S&P 500 finished above 12,000 and 1,300 points, resepctively, for the first time since mid-2008.
Pfizer Inc is to close its research and development center in Sandwich, southern England, which employs 2,400 people, dealing a major blow to Britain's scientific jobs base.
(Corrects that Pfizer bought Wyeth in late 2009, not last year, paragraph 8; error also occurred in previous updates)
U.S. stocks climbed on Tuesday on signs U.S. manufacturing surged and Pfizer Inc and UPS Inc posted strong results, sending indexes above key levels as market momentum strengthened.
U.S. stocks, led by Pfizer and Bank of America, surge.
US stocks extend gains in early trade on Tuesday after a report showed that manufacturing activity rose at a faster pace than expected in January.
Stocks were poised for a higher open on Tuesday as solid manufacturing data in Europe helped investors refocus attentions from the maelstrom in the Middle East to hopes that a global economic recovery was on track.
